Article

Medtronic invests in iScience Interventional

Medical technology company Medtronic Inc. has invested in iScience Interventional to support iScience?s efforts to develop and commercialize drug-delivery technologies for the eye.

Minneapolis and Menlo Park, CA-Medical technology company Medtronic Inc. has invested in iScience Interventional to support iScience’s efforts to develop and commercialize drug-delivery technologies for the eye.

iScience develops microcatheter and imaging technologies designed to enable ophthalmologists to deliver site-specific ocular therapies to reduce IOP in patients with moderate to advanced glaucoma and, in clinical trials, to deliver pharmaceutical and biologic therapies to the suprachoroidal and subretinal spaces to treat retinal diseases.

The company “has the potential to change how we address a wide range of ocular diseases,” said Steve Oesterle, MD, senior vice president for medicine and technology at Medtronic. “The ability to deliver drugs, biologics, devices, and cell therapies directly to the site of the diseases may redefine how we manage several of the most significant sight-threatening conditions of the eye.”

“This is a time of intense change in ophthalmology, and Medtronic’s understanding of catheters and interventional treatments is an excellent fit with our product portfolio and clinical development activities,” said Michael F. Nash, president and chief executive officer of iScience. “This [investment] will allow us to accelerate our ability to get innovative treatments to the market.”

Other investors in iScience include Asset Management Co., Prism VentureWorks, DeNovo Ventures, Three Arch Partners, Affinity Capital Management, Johnson & Johnson Development Corp., CHV Capital Inc., L Capital, and Sightline Partners

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.